Abstract: Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only a few cases of skin involvement have been reported, primarily in single case reports. We analyzed and present the clinical outcomes, immunohistochemistry and cytogenetic features, and relevant laboratory data on 53 biopsy-proven skin MM cases. The median time from MM diagnosis to skin involvement was 2 years. There appears to be an overrepresentation of immunoglobulin class A (IgA) and light chain disease in skin MM. We found no correlation between CD56 negative MM and skin infiltration. We found that skin MM patients presented in all MM stages (i.e. ISS stages I to III), and there was no preferential cytogenetic abnormality. Patients with skin MM carry a very poor prognosis with a median overall survival (OS) of 8.5 months as time from skin involvement. Moreover, patients with IgA disease and plasmablastic morphology appear to have a worse OS.

Jurczyszyn, A., Olszewska-Szopa, M., Hungria, V., Crusoe, E., Pika, T., Delforge, M., et al. (2016). Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. LEUKEMIA & LYMPHOMA, 57(9), 2071-2076 [10.3109/10428194.2015.1128542].

Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

Gozzetti, Alessandro;
2016-01-01

Abstract

Abstract: Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only a few cases of skin involvement have been reported, primarily in single case reports. We analyzed and present the clinical outcomes, immunohistochemistry and cytogenetic features, and relevant laboratory data on 53 biopsy-proven skin MM cases. The median time from MM diagnosis to skin involvement was 2 years. There appears to be an overrepresentation of immunoglobulin class A (IgA) and light chain disease in skin MM. We found no correlation between CD56 negative MM and skin infiltration. We found that skin MM patients presented in all MM stages (i.e. ISS stages I to III), and there was no preferential cytogenetic abnormality. Patients with skin MM carry a very poor prognosis with a median overall survival (OS) of 8.5 months as time from skin involvement. Moreover, patients with IgA disease and plasmablastic morphology appear to have a worse OS.
2016
Jurczyszyn, A., Olszewska-Szopa, M., Hungria, V., Crusoe, E., Pika, T., Delforge, M., et al. (2016). Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. LEUKEMIA & LYMPHOMA, 57(9), 2071-2076 [10.3109/10428194.2015.1128542].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1063227
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo